FDA says Ozempic, Wegovy are not in short supply anymore, which could impact prices
The U.S. Food and Drug Administration said Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply. CBS News New York reporter Ali Bauman reports on whether the supply change could lead to consumers paying more.
MedPage Today on MSN1d
Ozempic, Wegovy Shortage Is Officially OverThe shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...
ScienceAlert on MSN2d
Ozempic Literally Came From a Monster – And It's Not AloneThe toxic bite of a Gila monster can kill a human, but a specific ingredient in the cocktail of the lizard's venom is the ...
The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
Kwame Raoul is among several state AGs raising the alarm following complaints about online teleheath company Hims & Hers ...
The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback